EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy

Cancer Research

Volumn 64, Issue 16, 2004, Pages 5818-5824

  Osta, Walid A ^a   Chen, Yian ^a   Mikhitarian, Kaidi ^a   Mitas, Michael ^a   Salem, Mohamed ^a   Hannun, Yusuf A ^a   Cole, David J ^a   Gillanders, William E ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CELL ADHESION MOLECULE; DETERGENT; EPITHELIAL CELL ADHESION MOLECULE; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER INVASION; CANCER THERAPY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; EVIDENCE BASED MEDICINE; GENE THERAPY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALPHA CATENIN; ANTIGENS, NEOPLASM; BETA CATENIN; BREAST NEOPLASMS; CADHERINS; CELL ADHESION MOLECULES; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETAL PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENE THERAPY; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 4143074922     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0754     Document Type: Article

References (50)

1. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712.
2. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999;188:201-6.
3. High AS, Robinson PA, Klein CE. Increased expression of a 38kd cell-surface glycoprotein MH99 (KS 1/4) in oral mucosal dysplasias. J Oral Pathol Med 1996;25:10-3.
4. Litvinov SV, Bakker HA, Gourevitch MM, Velders MP, Warnaar SO. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun 1994;2:417-28.
5. Litvinov SV, van Driel W, van Rhijn CM, et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 1996;148:865-75.
6. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-46.
7. r 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-91.
8. Perez MS, Walker LE. Isolation and characterization of a cDNA encoding the KS 1/4 epithelial carcinoma marker. J Immunol 1989;142:3662-7.
9. Simon B, Podolsky DK, Moldenhauer G, et al. Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. Proc Natl Acad Sci USA 1990;87:2755-9.
10. Zorzos J, Zizi A, Bakiras A, et al. Expression of a cell surface antigen recognized by the monoclonal antibody AUA1 in bladder carcinoma: an immunohistochemical study. Eur Urol 1995;28:251-4.
11. Pauli C, Munz M, Kieu C, et al. Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Lett 2003;193:25-32.
12. Poczatek RB, Myers RB, Manne U, et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999;162:1462-6.
13. Shetye J, Christensson B, Rubio C, et al. The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. Anticancer Res 1989;9:395-404.
14. Spizzo G, Gastl G, Wolf D, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003;88:574-8.
15. Braun S, Hepp F, Kentenich CR, et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 1999;5:3999-4004.
16. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000;26:269-86.
17. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
18. Adkins JC, Spencer CM. Edrecolomab (monoclonal antibody 17-1A). Drugs 1998;56:619-26; discussion 627-8.
19. Herlyn D, Herlyn M, Ross AH, et al. Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods 1984;73:157-67.
20. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-2.
21. Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001;93:162-71.
22. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002;32:1372-4, 1376, 1378-9.
23. Elbashir SM, Harborth J, Lendeckel W, et al, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 2001;411:494-8.
24. Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 1994;125:1327-40.
25. Swets JA. Measuring the accuracy of diagnostic systems. Science (Wash DC) 1988;240:1285-93.
26. Mitas M, Hoover L, Silvestri G, et al. Lunx is a superior molecular marker for detection of non-small lung cell cancer in peripheral blood. J Mol Diagn 2003;5:237-42.
27. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science (Wash DC) 2002;296:550-3.
28. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002;20:1006-10.
29. Tuschl T. RNA interference and small interfering RNAs. Chembiochem 2001;2:239-45.
30. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
31. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997;139:1337-48.
32. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-57.
33. Basak S, Speicher D, Eck S, et al. Colorectal carcinoma invasion inhibition by COI7-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst (Bethesda) 1998;90:691-7.
34. Nagafuchi A, Takeichi M. Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul 1989;1:37-44.
35. Takeichi M, Hatta K, Nose A, Nagafuchi A, Matsunaga M. Cadherin-mediated specific cell adhesion and animal morphogenesis. Ciba Found Symp 1989;144:243-9; discussion 250-4, 290-5.
36. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994;127:1375-80.
37. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993;9:317-21.
38. Nathke IS, Hinck LE, Nelson WJ. Epithelial cell adhesion and development of cell surface polarity: possible mechanisms for modulation of cadherin function, organization and distribution. J Cell Sci Suppl 1993;17:139-45.
39. Balzar M, Prins FA, Bakker HA, et al. The structural analysis of adhesions mediated by Ep-CAM. Exp Cell Res 1999;246:108-21.
40. Huelsken J, Behrens J. The Wnt signalling pathway. J Cell Sci 2002;115:3977-8.
41. Korswagen HC, Herman MA, Clevers HC. Distinct beta-catenins mediate adhesion and signalling functions in C. elegans. Nature (Lond) 2000;406:527-32.
42. Hege KM, Carbone DP. Lung cancer vaccines and gene therapy. Lung Cancer 2003;41(Suppl 1):S103-13.
43. Kelley JR, Fraser MM, Hubbard JM, Watson DK, Cole DJ. CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer. Anticancer Res 2003;23:2007-13.
44. Zhang C, Liu ZK. Gene therapy for gastric cancer: a review. World J Gastroenterol 2003;9:2390-4.
45. Godbey WT, Atala A. Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery. Gene Ther 2003;10:1519-27.
46. Palmer K, Sharan N, Emtage P, et al. Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth. Gene Ther 2002;9:898-905.
47. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002;32:107-8.
48. McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature (Lond) 2002;418:38-9.
49. Mohmmed A, Dasaradhi PV, Bhamagar RK, Chauhan VS, Malhotra P. In vivo gene silencing in Plasmodium berghei: a mouse malaria model. Biochem Biophys Res Commun 2003;309:506-11.
50. Wang QC, Nie QH, Feng ZH. RNA interference: antiviral weapon and beyond. World J Gastroenterol 2003;9:1657-61.